IBRX
Price
$2.97
Change
-$0.08 (-2.62%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
2.53B
34 days until earnings call
NGENF
Price
$2.27
Change
+$0.18 (+8.61%)
Updated
Apr 2 closing price
Capitalization
151.99M
Ad is loading...

IBRX vs NGENF

Header iconIBRX vs NGENF Comparison
Open Charts IBRX vs NGENFBanner chart's image
ImmunityBio
Price$2.97
Change-$0.08 (-2.62%)
Volume$48.01K
Capitalization2.53B
NervGen Pharma
Price$2.27
Change+$0.18 (+8.61%)
Volume$172.4K
Capitalization151.99M
IBRX vs NGENF Comparison Chart
Loading...
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IBRX vs. NGENF commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBRX is a Hold and NGENF is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (IBRX: $2.97 vs. NGENF: $2.16)
Brand notoriety: IBRX and NGENF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBRX: 100% vs. NGENF: 210%
Market capitalization -- IBRX: $2.53B vs. NGENF: $151.99M
IBRX [@Biotechnology] is valued at $2.53B. NGENF’s [@Biotechnology] market capitalization is $151.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBRX’s FA Score shows that 1 FA rating(s) are green whileNGENF’s FA Score has 0 green FA rating(s).

  • IBRX’s FA Score: 1 green, 4 red.
  • NGENF’s FA Score: 0 green, 5 red.
According to our system of comparison, NGENF is a better buy in the long-term than IBRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBRX’s TA Score shows that 4 TA indicator(s) are bullish while NGENF’s TA Score has 4 bullish TA indicator(s).

  • IBRX’s TA Score: 4 bullish, 5 bearish.
  • NGENF’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, IBRX is a better buy in the short-term than NGENF.

Price Growth

IBRX (@Biotechnology) experienced а -11.61% price change this week, while NGENF (@Biotechnology) price change was +17.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

IBRX is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBRX($2.54B) has a higher market cap than NGENF($152M). IBRX YTD gains are higher at: 19.141 vs. NGENF (-0.917). NGENF has higher annual earnings (EBITDA): -27.5M vs. IBRX (-264.43M). IBRX has more cash in the bank: 150M vs. NGENF (21M). NGENF has less debt than IBRX: NGENF (129K) vs IBRX (504M). IBRX has higher revenues than NGENF: IBRX (14.7M) vs NGENF (0).
IBRXNGENFIBRX / NGENF
Capitalization2.54B152M1,668%
EBITDA-264.43M-27.5M962%
Gain YTD19.141-0.917-2,086%
P/E RatioN/AN/A-
Revenue14.7M0-
Total Cash150M21M714%
Total Debt504M129K390,698%
FUNDAMENTALS RATINGS
IBRX vs NGENF: Fundamental Ratings
IBRX
NGENF
OUTLOOK RATING
1..100
6822
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
81
Overvalued
PROFIT vs RISK RATING
1..100
10050
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6143
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBRX's Valuation (3) in the Biotechnology industry is significantly better than the same rating for NGENF (81) in the null industry. This means that IBRX’s stock grew significantly faster than NGENF’s over the last 12 months.

NGENF's Profit vs Risk Rating (50) in the null industry is somewhat better than the same rating for IBRX (100) in the Biotechnology industry. This means that NGENF’s stock grew somewhat faster than IBRX’s over the last 12 months.

NGENF's SMR Rating (100) in the null industry is in the same range as IBRX (100) in the Biotechnology industry. This means that NGENF’s stock grew similarly to IBRX’s over the last 12 months.

NGENF's Price Growth Rating (43) in the null industry is in the same range as IBRX (61) in the Biotechnology industry. This means that NGENF’s stock grew similarly to IBRX’s over the last 12 months.

NGENF's P/E Growth Rating (100) in the null industry is in the same range as IBRX (100) in the Biotechnology industry. This means that NGENF’s stock grew similarly to IBRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBRXNGENF
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 8 days ago
85%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 11 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NL7.870.26
+3.42%
NL Industries
WMK79.150.77
+0.98%
Weis Markets
ACHC28.36-0.85
-2.91%
Acadia Healthcare Company
LOW222.52-12.76
-5.42%
Lowe's Companies
ACET0.67-0.05
-7.32%
Adicet Bio

IBRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBRX
1D Price
Change %
IBRX100%
+3.04%
AXON - IBRX
48%
Loosely correlated
+3.18%
ARRY - IBRX
41%
Loosely correlated
+1.65%
CLRB - IBRX
38%
Loosely correlated
+3.46%
AMRN - IBRX
37%
Loosely correlated
-2.26%
VCYT - IBRX
35%
Loosely correlated
+1.93%
More

NGENF and

Correlation & Price change

A.I.dvisor tells us that NGENF and CYTK have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NGENF and CYTK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGENF
1D Price
Change %
NGENF100%
-4.85%
CYTK - NGENF
25%
Poorly correlated
+0.67%
IBRX - NGENF
23%
Poorly correlated
-2.62%
TNFA - NGENF
22%
Poorly correlated
+0.02%
CARM - NGENF
22%
Poorly correlated
-13.55%
ATRA - NGENF
22%
Poorly correlated
-3.43%
More